PATHWAY anti-HER2/neu (4B5) Rabbit Monoclonal Antibody is the first and only FDA-approved companion diagnostic for the breakthrough designated therapy ENHERTU®* (fam-trastuzumab deruxtecan-nxki) to identify HER2-low expression in metastatic breast cancer (mBC) patients who may be eligible for targeted therapy.
*For more information on ENHURTU® please refer to the FDA-approved product labeling
Test Centers
To have your lab featured here, please complete this form.
